Intracellular drug measurements to predict toxicity in high-dose methotrexate therapy in leukaemia and centralnervous system lymphoma.
- Conditions
- leukaemia and central nervous system lymphomaacute leukemie en centraal zenuwstelsel lymfoom
- Registration Number
- NL-OMON24644
- Lead Sponsor
- Erasmus Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
All adult patients treated in the Erasmus MC with HD-MTX for a CNS lymphoma or ALL
- Written informed consent
Exclusion Criteria
none
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To investigate the pharmacokinetics and determinants of MTX-PG accumulation in plasma, lymphocytes and erythrocytes in<br>adult CNS lymphoma and leukemia patients treated with HD-MTX
- Secondary Outcome Measures
Name Time Method To investigate whether intracellular MTX levels are related to toxicity in adult HD-MTX therapy